The story of Viagra and its parent , copyright, presents a complex picture for cautious investors. While the revolutionary drug initially produced enormous profits , its protection has expired , leading to here competing alternatives flooding the arena. This erosion in pricing presents a real challenge for copyright and any fund considering a signi